Canton Strategic Holdings (CNTN) Return on Capital Employed (2022 - 2026)
Canton Strategic Holdings posted quarterly Return on Capital Employed of 7.84% for Q1 2026, up 583890.0% year-on-year from N/an in Q1 2025, and down 130.76% on a QoQ basis from 3.4% in Q4 2025.
Canton Strategic Holdings (CNTN) has 5 years of Return on Capital Employed data on file, last reported at 7.84% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 583890.0% year-over-year to 7.84%; the trailing twelve-month figure through Mar 2026 stood at 7.84% (up 583890.0% YoY), and the FY2025 full-year result was 3.43%, up 24861.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 7.84%, down from 3.4% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 18004.79% in Q2 2025 and bottomed at 5846.74% in Q1 2025.
- The 5-year median for Return on Capital Employed is 129.79% (2024), against an average of 557.55%.
- Peak annual rise in Return on Capital Employed reached 1813458 bps in 2025, while the deepest fall reached 573424 bps in 2025.
- A 5-year view of Return on Capital Employed shows it stood at 110.85% in 2022, then slumped by 63 bps to 180.39% in 2023, then tumbled by 232 bps to 598.32% in 2024, then surged by 99 bps to 3.4% in 2025, then sank by 131 bps to 7.84% in 2026.
- The last three Return on Capital Employed figures came in at 7.84% (Q1 2026), 3.4% (Q4 2025), and 288.64% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 20.34% |
| 10 | Canton Strategic Holdings | 643.89 Mn | 602.36 Mn | - | -7.84% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.84% |
| Dec 31, 2025 | -3.40% |
| Sep 30, 2025 | -288.64% |
| Jun 30, 2025 | 18,004.79% |
| Mar 31, 2025 | -5,846.74% |
| Dec 31, 2024 | -598.32% |
| Sep 30, 2024 | -245.93% |
| Jun 30, 2024 | -129.79% |
| Mar 31, 2024 | -112.49% |
| Dec 31, 2023 | -180.39% |
| Sep 30, 2023 | -351.39% |
| Jun 30, 2023 | -286.64% |
| Mar 31, 2023 | -197.06% |
| Dec 31, 2022 | -110.85% |
| Sep 30, 2022 | -63.39% |
| Jun 30, 2022 | -36.45% |
| Mar 31, 2022 | -67.15% |